TMTP1-ICG Mapping in Laparoscopic SLN Detection in Cervical Cancer

Novel Tumor Targeted Fluorescent TMTP1-ICG Mapping in Laparoscopic Sentinel Lymph Node Detection in Cervical Cancer Patients

investigators aimed to determine the validity of our novel tumor targeted fluorescent TMTP1-ICG to increased accuracy of laparoscopic SLN mapping

Inclusion Criteria:

• At least 18 years of age, married, without childbearing requirements at the time of consent.
• FIGO stage IA1-IIB cervical squamous cell cancer and is a candidate for laparoscopy intervention, with lymph node dissection being a part of the surgical plan.
• Subject has provided written informed consent.

Exclusion Criteria:

• Breast-feeding or pregnant
• Ongoing participation in another clinical trial with an investigational drug with 3 months
• Own allergy towards ICG and/or alcohol
• Diagnosis of bacterial vaginosis, fungal vaginitis, sexually transmitted diseases
• Patients with cardiac dysfunction or hepatic insufficiency or renal insufficiency